Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed glioblastoma multiforme
• * Supratentorial
• * Grade IV astrocytoma
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 60-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 9.0 g/dL
• Hepatic
• Bilirubin no greater than 1.5 mg/dL
• Transaminases no greater than 4 times upper limit of normal
• Renal
• Creatinine no greater than 1.7 mg/dL
• Creatinine clearance at least 60 mL/min
• No prior renal toxicity with nonsteroidal anti-inflammatory drugs
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Mini mental score at least 15
• No history of peptic disease
• No serious concurrent infection
• No other medical illness that would preclude study participation
• No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer
• No allergy to sulfonamides
• Able to tolerate cyclo-oxygenase-2 (COX-2) inhibitors
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior immunotherapy or biologic agents for the malignancy, including any of the following:
• * Immunotoxins
• * Immunoconjugates
• * Antisense agents
• * Peptide receptor antagonists
• * Interferons
• * Interleukins
• * Tumor-infiltrating lymphocytes
• * Lymphokine-activated killer cells
• * Gene therapy
• No concurrent prophylactic growth factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])
• Chemotherapy
• No prior chemotherapy for the malignancy
• Endocrine therapy
• No prior hormonal therapy for the malignancy
• Prior glucocorticoid therapy allowed
• Concurrent corticosteroids allowed provided there has been no dose increase within the past 5 days
• Radiotherapy
• No prior radiotherapy for the malignancy
• Surgery
• Recovered from prior surgery
• Other
• At least 1 week since prior fluconazole
• More than 10 days since prior anticonvulsant drugs that induce hepatic metabolic enzymes (Group A)
• No other prior therapy for the malignancy
• No concurrent enrollment in another therapeutic clinical trial
• No concurrent fluconazole